Xtant Medical Holdings, Inc.
DB:XMS Lagerbericht
Marktkapitalisierung: €70.9m
Xtant Medical Holdings Balance Sheet Health
Finanzielle Gesundheit Kriterienprüfungen 5/6 Xtant Medical Holdings hat ein Gesamteigenkapital von $45.0M und eine Gesamtverschuldung von $33.7M, was einen Verschuldungsgrad von 74.8% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen $95.6M bzw. $50.6M.
Wichtige Informationen
74.8%
Verhältnis von Schulden zu Eigenkapital
Zinsdeckungsgrad n/a Bargeld US$5.38m Eigenkapital US$45.01m Gesamtverbindlichkeiten US$50.57m Gesamtvermögen US$95.58m
Jüngste Berichte zur Finanzlage
Xtant Medical Holdings, Inc. Regains Compliance with NYSE American Continued Listing Standards Oct 07
Alle Updates anzeigen
Xtant Medical Holdings, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Nov 07
New minor risk - Profitability Oct 18
Xtant Medical Holdings, Inc. Expands Product Portfolio with the Launch of the Cortera(R) Posterior Fixation System Sep 24
Xtant Medical Holdings, Inc. Expands Product Portfolio with Launch of its Own Viable Bone Matrix, OsteoVive(R) Plus Sep 18
New major risk - Share price stability Sep 05 Xtant Medical Holdings, Inc. announced that it has received $5 million in funding Aug 13
New minor risk - Shareholder dilution Aug 11
Second quarter 2024 earnings released: US$0.03 loss per share (vs US$0.02 loss in 2Q 2023) Aug 09
Xtant Medical Holdings, Inc. Reaffirms Earnings Guidance for the Full Year 2024 Aug 09 Xtant Medical Holdings, Inc. to Report Q2, 2024 Results on Aug 08, 2024
Xtant Medical Holdings, Inc., Annual General Meeting, Jul 23, 2024 Jun 13
New minor risk - Profitability Jun 07
New minor risk - Financial position May 17
Xtant Medical Holdings, Inc. Raises Revenue Guidance for the Full Year 2024 May 17
Xtant Medical Holdings, Inc. to Report Q1, 2024 Results on May 15, 2024 May 10
Xtant Medical Holdings, Inc. Announces Launch of SimpliGraft and SimpliMax for Chronic and Acute Wounds May 01
Xtant Medical Holdings, Inc. Announces Launch of SimpliGraft and SimpliMax for Chronic and Acute Wounds Apr 30
Xtant Medical Holdings, Inc. Provides Earnings Guidance for the Full Year 2024 Apr 03
Full year 2023 earnings released: EPS: US$0.006 (vs US$0.09 loss in FY 2022) Apr 02
Xtant Medical Holdings, Inc. to Report Q4, 2023 Results on Apr 01, 2024 Mar 22
Investor sentiment improves as stock rises 23% Feb 29
Xtant Medical Holdings, Inc. Revises Earnings Guidance for the Year 2023 Nov 10
Third quarter 2023 earnings released: EPS: US$0.072 (vs US$0.025 loss in 3Q 2022) Nov 10
Xtant Medical Holdings, Inc. to Report Q3, 2023 Results on Nov 09, 2023 Nov 03
Xtant Medical Holdings, Inc. (NYSEAM:XTNT) acquired NanOss Production Operations of RTI Surgical, Inc. for $2 million. Oct 24
Xtant Medical Holdings, Inc. (NYSEAM:XTNT) completed the acquisition of Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA). Aug 12
Xtant Medical Holdings, Inc. Raises Revenue Guidance for the Year 2023 Aug 03
Second quarter 2023 earnings released: US$0.02 loss per share (vs US$0.02 loss in 2Q 2022) Aug 02
Xtant Medical Holdings, Inc. to Report Q2, 2023 Results on Aug 01, 2023 Jul 26 Xtant Medical Holdings, Inc. announced that it expects to receive $15 million in funding Jul 04
Xtant Medical Holdings, Inc. (NYSEAM:XTNT) entered into asset purchase agreement to acquire Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA) for $5 million. Jun 21
Xtant Medical Holdings, Inc. Appoints Lori Mitchell-Keller to Board of Directors May 19
First quarter 2023 earnings released: US$0.019 loss per share (vs US$0.025 loss in 1Q 2022) May 07
Xtant Medical Holdings, Inc. Announces Executive Changes May 06
Xtant Medical Holdings, Inc. Provides Revenue Guidance for the Full Year 2023 May 05
Full year 2022 earnings released: US$0.09 loss per share (vs US$0.057 loss in FY 2021) Mar 09
Xtant Medical Holdings, Inc., Annual General Meeting, Jul 26, 2023 Feb 02
Xtant Medical Holdings, Inc. Appoints Mark Schallenberger as Chief Operations Officer, Effective January 16, 2023 Jan 10
Less than half of directors are independent Nov 16
Third quarter 2022 earnings released: US$0.025 loss per share (vs US$0.021 loss in 3Q 2021) Nov 04
Xtant Medical Holdings, Inc. to Report Q3, 2022 Results on Nov 03, 2022 Oct 28
Xtant Medical Holdings, Inc., Annual General Meeting, Oct 26, 2022 Sep 01 Xtant Medical Holdings, Inc. announced that it expects to receive $9.746606 million in funding
Second quarter 2022 earnings released: US$0.02 loss per share (vs US$0.008 loss in 2Q 2021) Aug 05
Xtant Medical Holdings, Inc. to Report Q2, 2022 Results on Aug 04, 2022 Jul 29
First quarter 2022 earnings released: US$0.025 loss per share (vs US$0 in 1Q 2021) May 06
Xtant Medical Holdings, Inc. Announces the Appointment of Scott Neils as Chief Financial Officer, Effective June 1, 2022 May 03
Less than half of directors are independent Apr 27
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Mar 09
Xtant Medical Holdings, Inc. to Report Q4, 2021 Results on Mar 08, 2022 Mar 03
Third quarter 2021 earnings released: US$0.021 loss per share (vs US$0.10 loss in 3Q 2020) Nov 13
Second quarter 2021 earnings released: US$0.008 loss per share (vs US$0.19 loss in 2Q 2020) Aug 09
Xtant Medical Holdings, Inc. announced that it has received $20.000003 million in funding Feb 26
Full year 2020 earnings released: US$0.25 loss per share (vs US$0.63 loss in FY 2019) Feb 25
Xtant Medical Holdings, Inc. announced that it expects to receive $20.000003 million in funding Feb 24
Xtant Medical Holdings, Inc. to Report Q4, 2020 Results on Feb 24, 2021 Feb 18
New 90-day high: €1.49 Feb 11
New 90-day high: €1.20 Jan 24
Third quarter earnings released Oct 30
Third-quarter earnings released: Revenue misses expectations Oct 30
Xtant Medical Holdings, Inc. Regains Compliance with NYSE American Continued Listing Standards Oct 07 Xtant Medical Holdings, Inc. announced that it expects to receive $62.882 million in funding
New 90-day low: €0.65 Sep 28
New 90-day low - €0.66 Sep 11
New 90-day low - €0.76 Aug 21
First half earnings released Aug 04
Xtant Medical Holdings, Inc. to Report Q2, 2020 Results on Aug 03, 2020 Jul 31
Xtant Medical Holdings, Inc.(AMEX:XTNT) dropped from Russell Microcap Growth Index Jul 05
Xtant Medical Holdings, Inc.(AMEX:XTNT) dropped from Russell Microcap Index Jul 02
Analyse der Finanzlage
Kurzfristige Verbindlichkeiten: XMSDie kurzfristigen Aktiva des Unternehmens ($69.0M) übersteigen seine kurzfristigen Passiva ($28.3M).
Langfristige Verbindlichkeiten: XMSDie kurzfristigen Vermögenswerte des Unternehmens ($69.0M) übersteigen seine langfristigen Verbindlichkeiten ($22.3M).
Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital
Verschuldungsgrad: XMSDie Nettoverschuldung im Verhältnis zum Eigenkapital (62.9%) wird als hoch angesehen.
Schulden abbauen: XMS hatte vor 5 Jahren ein negatives Eigenkapital, ist jetzt aber positiv und hat sich somit verbessert.
Liquiditätsreserve-Analyse Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.
Stabile Start- und Landebahn für Bargeld: XMS verfügt auf der Grundlage des zuletzt gemeldeten freien Cashflow s über eine ausreichende Liquiditätsreserve für 4 Monate. [freien Cashflow]], hat aber seitdem zusätzliches Kapital aufgenommen.
Vorhersage Cash Runway: XMS verfügt über eine ausreichende Liquiditätsreserve für 2.5 Jahre, wenn der freie Cashflow weiterhin mit historischen Raten von 52.4% pro Jahr abnimmt.
Entdecken Sie finanziell stabile Unternehmen Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}